Thursday, September 17th, 2020

09:00 // Registration, Coffee & Mingling

09:25 // Welcome

09:30 // SESSION 1: Will molecular tests enable sustainable precision medicine? 

               Chair: Kristin Austlid Taskén, Oslo University Hospital (NOR)

09:30 // How to use new biomarkers in treatment guidance of men with early prostate cancer?

              Stacy Loeb, New York University and the Manhattan Veterans Affairs Medical Center (US)

10:00 // Will biomarkers - other than PSA - be used to guide treatment of advanced prostate cancer?

              Nicolas Mottet,  University Hospital St. Etienne and University Jean Monnet  (FRA)

10:30 // How to identify biomarkers with a beneficial cost-effectiveness profile?

              Jack Schalken,  Radboud University (NL)

11:00 // Break

11:30 // Biomarker-driven precision medicine in Norway - where we are and where to go

    Hege Russnes, Oslo University Hospital (NOR)

11:45 // Panel Discussion (in Norwegian) - How and when can molecular tests provide sustainable, precision   

              in the clinic?

             Moderator Elisabeth Kirkeng Andersen (NOR)

13:00 // Lunch

14:00 // SESSION 2: Providing evidence for implementing molecular tests in clinical guidelines

              Chair: Rolf Skotheim, Oslo University Hospital (NOR)

14:00 // Requirements for implementation of molecular tests into guidelines

              Himisha Beltran, Dana-Farber Cancer Institute and Harvard Medical School (US)

14:30 // Molecular stratification in clinical trials

              Johann de Bono, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust (UK)

15:00 // Break

15:30 // Design of biomarker-driven clinical trials

              Jason Connor, University of Central Florida's College of Medicine and ConfluenceStat LLC (US)

16:00 // How to bring molecular tests into the clinic in Scandinavia

              Henrik Grønberg, Karolinska Institutet and Capio S:t Göran Hospital (SWE)

16:30 // Short talk - selected from abstracts

16:40 // Short talk - selected from abstracts

17:00 // Poster session (incl. Coffee and snacks)

18:00 // Social activity and dinner including Poster Awards (Munch museum)


Friday, September 18th, 2020

09:00 // SESSION 3: Precision medicine: impact of the tumour environment 

              Chair: Heidi Lyng, Oslo University Hospital, Oslo, Norway.

09:00 // Everything in balance? Metabolism reprograms cells

              Ian Mills, University of Oxford, Queen’s University of Belfast and University of Cambridge (UK) ​

09:30 // Hypoxia and subclonal evolution 

              Rob Bristow, Manchester Cancer Research Centre, CRUK Major research Centre, University of Manchester (UK)

10:00 // How can we move forward with immunotherapy in prostate cancer?  

              Johanna Olweus, Oslo University Hospital (NOR)

10:15 // Break

10:45 // Discovery and testing of biomarkers and drugs in ex vivo and in vivo model systems

              Wytske van Weerden, Erasmus Medical Center (NL)

11:15 // Short talk - selected from abstracts

11:30 // Lunch 

12:30 // Drug efficacy in ex vivo model systems

              Olli Kallioniemi, Karolinska Institutet (SWE)

13:00 // SESSION 4: Pitfalls and opportunities in biomarker discovery

              Alicia Llorente, Oslo University Hospital (NOR)

13:00 // Tumor heterogeneity: a challenge to biomarker research

              Håvard Danielsen, Oslo University Hospital (NOR)

13:15 // Lineage plasticity in prostate cancer

              Mark Rubin, University of Bern (CH)

13:45 // Extracellular vesicles - from lab to clinical implementation

              Johan Skog, Exosome Diagnostics (US) 

14:15 // Break

14:45 // Exploring precision oncology: From gene fusions to lncRNAs

              Arul Chinnaiyan, Michigan Center for Translational Pathology and Howard Hughes Medical Institute (US)

14:55 // European network for biomarker validation

              Guido Jenster, Erasmus Medical Centre (NL)

15:25 // Closing remarks